By Luke Gill
Evaluation of patient response to treatment of solid tumors is undergoing an important evolution under the new iRECIST guidance issued in early 2017. The RECIST 1.1 guideline remains the gold standard, but iRECIST is focusing attention on the future of tumor assessment methods.
Here are five things you should know about iRECIST as the standard shapes up as an important tool in assessing solid tumors.